Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Inventory (2022 - 2025)

Immunocore Holdings (IMCR) has disclosed Inventory for 4 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 23.8% to $6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Dec 2025, up 23.8% year-over-year, with the annual reading at $6.7 million for FY2025, 23.8% up from the prior year.
  • Inventory hit $6.7 million in Q4 2025 for Immunocore Holdings, up from $5.7 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $6.8 million in Q1 2025 to a low of $1.1 million in Q4 2022.
  • Historically, Inventory has averaged $4.8 million across 4 years, with a median of $5.0 million in 2024.
  • Biggest five-year swings in Inventory: skyrocketed 306.94% in 2023 and later increased 21.0% in 2024.
  • Year by year, Inventory stood at $1.1 million in 2022, then soared by 306.94% to $4.5 million in 2023, then grew by 21.0% to $5.4 million in 2024, then increased by 23.8% to $6.7 million in 2025.
  • Business Quant data shows Inventory for IMCR at $6.7 million in Q4 2025, $5.7 million in Q3 2025, and $5.5 million in Q2 2025.